Nasdaq: $25.89 (-0.35) | AIM: £3.70 (-0.26)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 1 Apr 2014

AACR 2014: Anti-tumour activity of Epitinib in patient derived esophagus cancer models